Lipoprotein(a.), apolipoprotein A-I and B serum levels in young families from Tallinn, Estonia. Relationships with other cardiovascular risk factors and nationality

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 59, Issue 3, 1999, Pages 179-189

  Aasvee, Katrin ^a   Jauhiainen, M ^b   Kurvinen, E ^a   Jordania, R ^a   Sundvall, J ^b   Ehnholm, C ^b  

^a Estonian Institute of Cardiology   (Estonia)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Apolipoproteins; Lipids; Lipoprotein(a); Newborns; Risk factors; Young adults

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; APGAR SCORE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; ESTONIA; ETHNIC DIFFERENCE; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN EXPERIMENT; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; MALE; NEWBORN; NEWBORN SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033039850     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519950185706     Document Type: Article

References (60)

1. Volozh O, Dejev A, Kaljuste T, Kaup R, Solodkaja E, Abina J. Prediction of coronary heart disease mortality in the population of Estonia on the basis of long-term follow-up studies. Estonian Physician 1997: 325-30.
2. Avogaro P, Bittolo-Bon G, Cazzolato G, Quinci GB. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet 1979; 1: 901-3.
3. Durrington PN, Hunt L, Ishola M, Kane J, Stephens WP. Serum apolipoproteins A-I and B and lipoproteins in middle-aged men with and without previous myocardial infarction. Br Heart J 1986; 56: 206-12.
4. Naito HK. The clinical significance of apolipoprotein measurement. J Clin Immuno-assay 1986; 9: 11-20.
5. Bolibar I, Thompson SG, von Eckardstein A, Sandkamp M, Assmann G on behalf of the ECAT Angina Pectoris Study Group. Dose-response relationships of serum lipid measurements with the extent of coronary stenosis. Arterioscler Thromb Vasc Biol 1995; 15: 1035-42.
6. Linden T, Taddei-Peters W, Wilhelmsen L, Herlitz J, Karlsson T, Ullstr̈m C, Wiklund O. Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis 1998; 137: 175-86.
7. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963; 59: 211-20.
8. Ehnholm C, Garoff H, Renkonen O, Simons K. Protein and carbohydrate composition of Lp(a) lipoprotein from human plasma. Biochemistry 1972; 11: 3229-32.
9. Gunther MF, Rolih CA, Scanu AM. Heterogenity of human plasma lipoprotein(a). Isolation and characterization of the lipoprotein subspecies and their apolipoproteins. J Biol Chem 1984; 259: 11470-8.
10. White A, Lanford RE. Biosynthesis and metabolism of lipoprotein(a). Curr Opin Lipidol 1995; 6: 75-80.
11. McLean JW, Tomlinson JE, Kuang W, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 300: 132-7.
12. Miles L, Fless GM, Scanu AM, Baynham P, Sebald MT, Skocir P, Curtiss LK, Lewin EG, Hoover-Plow JL, Plow EF. Interaction of Lp(a) with plasminogen binding sites on cells. Thromb Haemost 1995; 73: 458-65.
13. Pursiainen M, Jauhiainen M, Kovanen PT, Ehnholm C. Proteolytic degradation of low-density lipoprotein by lipoprotein(a) and by recombinant apo(a). Chem Phys Lipids 1994; 67/68: 25-33.
14. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52-60.
15. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Quinci GB. Lipoprotein Lp(a) and the risk of myocardial infarction. Atherosclerosis 1981; 38: 51-61.
16. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758-65.
17. Cremer P, Nagel P, Mann H, Labrot B, Müller-Berninger R, Thiery J, Seidel D. Ranking of Lp(a) as a cardiovascular risk factor: results from a 10-year prospective study. In: Woodford FP, Davignon J, Sniderman, A, editors. Atherosclerosis X. Amsterdam: Elsevier Science, 1995: 903-7.
18. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.
19. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-9.
20. Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle E, Hillis LD, Hobbs HH. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol 1995; 15: 850-5.
21. Helmhold M, Bigge J, Muche R, Mainoo J, Thiery J, Seidel D, Armstrong VW. Contribution of the apo(a) phenotype to plasma Lp(a) concentration shows considerable ethnic variation. J Lipid Res 1991; 32: 1919-28.
22. Harris MR, Bunker CH, Hamman RF, Sanghera DK, Aston CE, Kamboh MI. Racial differences in the distribution of a low density lipoprotein receptor-related protein (LRP) polymorphism and its association with serum lipoprotein, lipid and apolipoprotein levels. Atherosclerosis 1998; 137: 187-95.
23. Klausen IC, Beisiegel U, Menzel H-J, Rosseneu M, Nicaud V, Faergeman O on behalf of the EARS Group. Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction. Arterioscler Thromb Vasc Biol 1995; 15: 1001-8.
24. Volozh O, Saava M, Tur I, Solodkaja E, Galperina T, Abina J, Olferiev A. Ethnic differences in coronary heart disease risk factors in Estonia. Cardiovascular Risk Factors 1995; 5: 305-10.
25. Aasvee K, Saava M, Sink R. Serum apolipoproteins A-I and B in relation to nutrition and other cardiovascular risk factors in school children of Tallinn. Atherosclerosis 1994; 109: 139-40.
26. Behrman RE, Vaughan VC, Nelson WE. Nelson Textbook of Pediatrics. Thirteenth edition. W. B. Saunders Company, Philadelphia 1987.
27. Kronenberg F, Lobentanz E-M, König P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res 1994; 35: 1318-28.
28. Sundvall J, Sulonen G-B, Hiltunen O, Kiuru J, Pursiainen M, Jauhiainen M. Comparison of a new immunoturbidimetric assay of human serum lipoprotein(a) to the ELISA and the IRMA methods. Scand J Clin Lab Invest 1995; 55: 171-80.
29. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-5.
30. Lipid Research Clinics Program. Manual of Laboratory Operations, vol 1: lipid and lipoprotein analysis. DHEW publication No (NIH): 75-628. Bethesda (MD): National Institutes of Health; 1974.
31. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
32. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52.
33. Riepponen P, Marniemi J, Rautaoja T. Immunoturbidimetric determination of apolipoproteins A-I and B in serum. Scand J Clin Lab Invest 1987; 47: 739-44.
34. Baburin A, Gornoi K, Leinsalu M, Rahu M. Atlas of mortality in Estonia. Printall, Tallinn 1997.
35. Aasvee K, Saava M, Sink R. Serum apolipoproteins A-I and B in relation to dietary pattern and level of physical activity in schoolchildren of Tallinn. Acta et Commentationes Universitatis Tartuensis, 1993; 958: 37-40.
36. Cheung MC, Albers JJ. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res 1982; 23: 747-53.
37. Fielding CJ. Reverse cholesterol transport. Curr Opin Lipidol 1991; 2: 376-8.
38. Fruchart JC, De Geteire C, Delfy B, Castro GR. Apolipoprotein A-I containing particles and reverse cholesterol transport: Evidence for connection between cholesterol efflux and atherosclerosis risk. Atherosclerosis 1994; Suppl: S35-9.
39. Rader SY, Castro GR, Zech LA, Fruchart JC, Brewer HB Jr. In vivo metabolism of apolipoprotein A-I on high-density lipoprotein particles LpA-I and LpA-I: A-II. J Lipid Res 1991; 32: 1849-59.
40. Phillips MC, Gillote K, Lund-Katz S, Johnson W, Rothblat G. High density lipoproteins and cellular cholesterol efflux. In: Jacotot B, Mathé D, Fruchart J-C, editors. Atherosclerosis XI. Singapore: Elsevier Science, 1998: 861-5.
41. Asztalos BF, Roheim PS. Presence and formation of "free apolipoprotein A-I-like" particles in human plasma. Arterioscler Thromb Vasc Biol 1995; 15: 1419-23.
42. Volozh OI, Zhdanov VS, Zhukovski GS, Solodkaya ES, Galakhov EE, Semenov AS, Konstantinov VV, Burlutskii GI, Olferiev AM. Ischaemic heart disease in men of productive age: comparison of epidemiological and morphological data. Cor Vasa 1992; 34: 199-208.
43. Antal M, Bintó EK, Szépvölgyi J, Nagy K, Biró L, Ågfalvy R, Sagi K, Greiner E, Regöly AM, Biró G. Cardiovascular risk factors in Hungarian adolescents. Can J Cardiol 1997; 13 Suppl B: 221B.
44. Cigolini M, Seidell JC, Zenti MG, Bonadonna G, Zambelli L, Deslypere JP, Contaldo F, Cruz A, Charzewska J, Targher G. Serum Lp(a) levels in randomized healthy men from different European countries. Eur J Epidemiol 1993; 9: 497-503.
45. Bostom AG, Gagnon DR, Cupples LA, Wilson PW, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. Circulation 1994; 90: 1688-95.
46. Utermann G, Menzel HJ, Kraft HG, Kemmler MG, Seitz C. Lp(a) glycoprotein phenotypes' inheritance and relations to Lp(a) concentrations in plasma. J Clin Invest 1987; 8: 458-65.
47. Slunga L, Asplund K, Johnson O, Dahlen GH. Lipoprotein(a) in a randomly selected 25-64 year old population: the Northern Sweden Monica Study. J Clin Epidemiol 1993; 46: 617-24.
48. Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PW, Castelli WP, Schaefer EJ. Effects of age, sex, and menopausal status on plasma lipoprotein levels. The Framingham Offspring Study. Circulation 1993, 87: 1135-41.
49. Braeckman L, De Bacquer D, Rosseneu M, De Backer G. Determinants of lipoprotein(a) levels in a middle-aged working population. Eur Heart J 1996; 17: 1808-13.
50. Holme I, Urdal P, Anderssen S, Hjermann I. Exercise induced increase in lipoprotein(a). Atherosclerosis 1996; 122: 97-104.
51. Lobo RA, Notelovitz M, Bernstein L, Khan FY, Ross RK, Paul WL. Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen. Am J Obstet Gynecol 1992; 166: 1182-88.
52. Steinmetz A, Kirklies A, Schlosser G, Cassel W, Peter JH, Ehlenz K, Schaefer JR, Wiehert PV, Kaffarnic H. Lipoprotein(a), low-density, intermediate-density lipoprotein, and blood pressure in a young male population. Clin Investigator 1993; 71: 145-9.
53. Slunga L, Johnson O, Dahlen GH, Eriksson S. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest 1992; 52: 95-101.
54. Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis 1985; 5: 265-72.
55. Taimela S, Viikari JSA, Porkka KVK, Dahlen GH. Lipoprotein(a) levels in children and young adults: the influence of physical activity. The cardiovascular risk in young Finns study. Acta Paediatr 1994; 83: 1258-63.
56. Seed M. Lipoprotein(a) - its role in cardiovascular disease. In: Betteridge DJ, editor. Lipids: current perspectives I. Lipids and lipoproteins. London: Martin Dunitz Ltd, 1996: 69-88.
57. Argraves KMCT, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK. The human very low density lipoprotein receptor mediates the uptake and degradation of lipoprotein(a). In: Jacotot B, Mathé D, Fruchart J-C, editors. Atherosclerosis XI. Amsterdam: Elsevier Science, 1998: 559-65.
58. Martyn CN, Barker DJP. The fetal origins of cardiovascular disease. In: Woodford FP, Davignon J, Sniderman A, editors. Atherosclerosis X. Amsterdam: Elsevier Science, 1995: 914-8.
59. Miura K, Nakagawa H, Ikawa A, Nishi M, Morikawa Y, Nishijo M, Tabata M, Kawano S. Blood pressure, serum cholesterol at age 20 and birth weight: a 20 year follow-up of Japanese population. Can J Cardiol 1997; 13 Suppl B: 348B.
60. Routi T, Rönnemaa T, Jokinen E, Viikari J, Niinikoski H, Leino A, Simell O. Correlation of toddlers's serum lipoprotein(a) concentration with parental values and grandparents' coronary heart disease: the STRIP baby study. Acta Paediatr 1996; 85: 407-12.